Modality
ASO
MOA
VEGFi
Target
CD123
Pathway
DDR
Gastric Ca
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
~Dec 2018
→ ~Mar 2020
NDA/BLA
Jun 2020
→ Aug 2029
NDA/BLACurrent
NCT03188195
351 pts·Gastric Ca
2020-06→2029-08·Completed
351 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-133.4y awayPh3 Readout· Gastric Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2029-08-13 · 3.4y away
Gastric Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03188195 | NDA/BLA | Gastric Ca | Completed | 351 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Gozeosocimab | Illumina | Phase 2 | BCMA | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| RLA-8772 | Relay Therapeutics | Phase 2 | MALT1 |